Impact of Brokerage Rating on Vertex Pharmaceuticals Incorporated(VRTX)

Many Vertex Pharmaceuticals Incorporated(VRTX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Vertex Pharmaceuticals Incorporated was Reiterated by Stifel on Jan 26, 2017 to Buy, Lowers Price Target to $ 100 from a previous price target of $108 .Vertex Pharmaceuticals Incorporated was Initiated by Oppenheimer to Perform on Dec 15, 2016.

Company has reported several Insider transactions to the SEC, on Feb 3, 2017, Michael Parini (EVP, CLO & CAO) sold 3,450 shares at 85.98 per share price.On Feb 3, 2017, Jeffrey Chodakewitz (EVP GMDA, CMO) sold 1,900 shares at 85.50 per share price.On Jan 13, 2017, Joshua S Boger (director) sold 8,000 shares at 83.15 per share price.

Vertex Pharmaceuticals Incorporated Last issued its quarterly earnings results on Jan 25, 2017. The company reported $0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $0.29.Analysts expectations of $ 452.50.During the same quarter in the previous year, the company posted $0.17 EPS.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.19 by 18 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 10 Brokerage Firms have advised hold.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): 14 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $103.5 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). However, the stock price could fluctuate by $ 18.12 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $139 price target with the lower price estimate is calculated at $75

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rose 1.36% or 1.19 points on Tuesday and made its way into the gainers of the day. After trading began at $87.89 the stock was seen hitting $89.26 as a peak level and $87.34 as the lowest level. The stock ended up at $88.91. The daily volume was measured at 2,321,559 shares. The 52-week high of the share price is $103.73 and the 52-week low is $71.46. The company has a market cap of $22,053 million.

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Vertex

For any feedback and suggestions contact author at Nancy.Wright@thefoundersdaily.com

Add Comment